These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 21884030)

  • 21. Lowered B-type natriuretic peptide in response to levosimendan or dobutamine treatment is associated with improved survival in patients with severe acutely decompensated heart failure.
    Cohen-Solal A; Logeart D; Huang B; Cai D; Nieminen MS; Mebazaa A
    J Am Coll Cardiol; 2009 Jun; 53(25):2343-8. PubMed ID: 19539144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience.
    Parle NM; Thomas MD; Dembo L; Best M; Driscoll GO
    Heart Lung Circ; 2008 Jun; 17(3):206-10. PubMed ID: 18242130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of levosimendan on B-type natriuretic peptide levels in patients with advanced heart failure: a meta-analysis].
    Xu ZD; He WX; Zhao YF; Xia SX; He B; Yang T; Cao DX; Peng SL; Li J; Cao MH
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Oct; 29(10):2027-9. PubMed ID: 19861257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
    Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
    Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
    Giamouzis G; Giannakoulas G; Tsarpalis K; Agha SA; Georgiopoulou V; Kalogeropoulos A; Karvounis H; Butler J
    Int J Cardiol; 2008 Aug; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
    [No Abstract]   [Full Text] [Related]  

  • 26. Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure.
    Ikonomidis I; Parissis JT; Paraskevaidis I; Kourea K; Bistola V; Lekakis J; Filippatos G; Kremastinos DT
    Eur J Heart Fail; 2007 Dec; 9(12):1172-7. PubMed ID: 18062901
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation.
    Zemljic G; Bunc M; Yazdanbakhsh AP; Vrtovec B
    J Card Fail; 2007 Aug; 13(6):417-21. PubMed ID: 17675054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
    Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
    Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients.
    Kyrzopoulos S; Adamopoulos S; Parissis JT; Rassias J; Kostakis G; Iliodromitis E; Degiannis D; Kremastinos DT
    Int J Cardiol; 2005 Mar; 99(3):409-13. PubMed ID: 15771921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of levosimendan on markers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure.
    Parissis JT; Panou F; Farmakis D; Adamopoulos S; Filippatos G; Paraskevaidis I; Venetsanou K; Lekakis J; Kremastinos DT
    Am J Cardiol; 2005 Aug; 96(3):423-6. PubMed ID: 16054474
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levosimendan infusion improves haemodynamics in elderly heart failure patients undergoing urgent hip fracture repair.
    Ponschab M; Hochmair N; Ghazwinian N; Mueller T; Plöchl W
    Eur J Anaesthesiol; 2008 Aug; 25(8):627-33. PubMed ID: 18405408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure.
    Packer M; Colucci W; Fisher L; Massie BM; Teerlink JR; Young J; Padley RJ; Thakkar R; Delgado-Herrera L; Salon J; Garratt C; Huang B; Sarapohja T;
    JACC Heart Fail; 2013 Apr; 1(2):103-11. PubMed ID: 24621834
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Possibilities of using levosimendan in patients with idiopathic pulmonary hypertension].
    Martyniuk TV; Arkhipova OA; Kobal' EA; Danilov NM; Chazova IE
    Ter Arkh; 2012; 84(9):83-8. PubMed ID: 23091860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dobutamine-induced changes of left atrial two-dimensional deformation predict clinical and neurohumoral improvement after levosimendan treatment in patients with acutely decompensated chronic heart failure.
    Paraskevaidis IA; Ikonomidis I; Parissis J; Papadopoulos C; Stassinos V; Bistola V; Anastasiou-Nana M
    Int J Cardiol; 2012 May; 157(1):31-7. PubMed ID: 21176979
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Levosimendan in decompensated heart failure patients: efficacy in a Brazilian cohort. Results of the BELIEF study.
    Bocchi EA; Vilas-Boas F; Moreira Mda C; Barretto AC; Lage S; Albuquerque D; Baima J; Rassi S; Ribeiro JP; ;
    Arq Bras Cardiol; 2008 Mar; 90(3):182-90. PubMed ID: 18392398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levosimendan and nesiritide as a combination therapy in patients with acute heart failure.
    Jia Z; Guo M; Zhang LY; Zhang YQ; Liang HQ; Song Y
    Am J Med Sci; 2015 May; 349(5):398-405. PubMed ID: 25853935
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients: direct evidence from sympathetic neural recording.
    Despas F; Trouillet C; Franchitto N; Labrunee M; Galinier M; Senard JM; Pathak A
    Acute Card Care; 2010 Mar; 12(1):25-30. PubMed ID: 19929264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of noninvasive hemodynamic evaluation of the acute effect of levosimendan in advanced heart failure.
    Malfatto G; Della Rosa F; Rella V; Villani A; Branzi G; Blengino S; Giglio A; Facchini M; Parati G
    J Cardiovasc Med (Hagerstown); 2014 Apr; 15(4):322-30. PubMed ID: 24699010
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short-term effect of levosimendan on free light chain kappa and lambda levels in patients with decompensated chronic heart failure.
    Kurt IH; Yavuzer K; Batur MK
    Heart Vessels; 2010 Sep; 25(5):392-9. PubMed ID: 20676961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duration of the beneficial effects of levosimendan in decompensated heart failure as measured by echocardiographic indices and B-type natriuretic peptide.
    McLean AS; Huang SJ; Nalos M; Ting I
    J Cardiovasc Pharmacol; 2005 Dec; 46(6):830-5. PubMed ID: 16306809
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.